Lion Biotechnologies deal increases visibility, says Roth Capital After Lion Biotechnologies (LBIO) and Immunocore entered into an agreement to co-discover and co-develop novel T-cell based cancer therapies. Roth Capital thinks the deal increases the visibility for T-cell therapies and is positive for Lion Biotechnologies. The firm sees the deal as an indication that large drug companies remain interested in the T-cell based immunotherapy space, and it thinks that Lion is well-positioned in the space. The firm reiterates a $20 price target and Buy rating on Lion.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: Diplomat Pharmacy (DPLO) initiated with an Outperform at RW Baird... Lion Biotechnologies (LBIO) initiated with a Buy at Jefferies... Madison Square Garden (MSG) initiated with a Hold at Jefferies... Synchrony Financial (SYF) initiated with a Positive at Susquehanna... Townsquare Media (TSQ) initiated with an Outperform at Barrington... Xylem (XYL) initiated with a Neutral at Boenning & Scattergood.